Children and young adults with a range of different childhood cancers are finding new hope in chimeric antigen receptor cell (CAR T-cell) trials offered at Seattle Children’s. CAR T-cell immunotherapy is one of the most promising experimental cancer therapies of our time. The ongoing clinical trials in Seattle were developed at Seattle Children’s Ben Towne Center for Childhood Cancer Research and Immunotherapy Integration Hub and represent the most comprehensive CAR T-cell immunotherapy program for pediatric patients anywhere, treating more types of childhood cancers using CAR T-cell therapies than any other facility worldwide.

Currently, 10 trials are underway.

Click here for information about the findings presented by Seattle Children’s researchers at the American Society of Hematology (ASH) Annual Meeting in December 2018.

In April 2017, Seattle Children’s published in Blood that:

  • 40 of 43 patients achieved complete initial remission during treatment in the phase 1 PLAT-02 clinical trial studying immunotherapy to treat relapsed acute lymphoblastic leukemia (ALL). This is a 93% initial remission rate.
  • Of the children who achieved initial remission, about 50% were still in remission 1 year after therapy. Some have now been in remission for more than 4 years.

The 10 clinical trials currently open to cancer patients at Seattle Children’s include:

  • BrainChild-01 and -02: For children and young adults who have relapsed or refractory brain or central nervous system (CNS) tumors that express the protein HER2 or EGFR.
  • ENCIT-01: For children and adolescents with recurrent or refractory neuroblastoma who are not likely to survive with current treatments.
  • HA-1 therapy: For children and young adults with relapsed or refractory acute myeloid leukemia (AML), T-cell ALL or B-cell ALL that does not respond to treatment after a donor stem cell transplant.
  • PLAT studies: For children and young adults with relapsed or refractory CD19+ or CD22+ acute leukemia or lymphoma who have not responded to standard therapies or who have relapsed after another T-cell therapy.
  • STRIvE-01: For children and young adults with relapsed or refractory solid tumors that express the protein EGFR.

Read how Texan teen Madeline Boese made a lifesaving comeback from recurring cancer after enrolling last year in CAR T-cell clinical trials in Seattle.